Experimental drug ALN-CIDEB targets fatty liver in early trial
NCT ID NCT06836609
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called ALN-CIDEB in adults with fatty liver conditions (MASLD or MASH). The main goal is to check safety and tolerability, and also to see if the drug can reduce liver fat. About 132 participants will receive either the drug or a placebo. This is an early-stage trial, so results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALN-CIDEB (an experimental drug)
What this could lead to
If it works, this could point toward a treatment that reduces liver fat and controls MASLD/MASH, potentially preventing progression to more severe liver damage.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 132 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show meaningful benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arizona Liver Health
RECRUITINGChandler, Arizona, 85225, United States
-
Parexel International Early Phase Clinical Unit
RECRUITINGHarrow, London, HA1 3UJ, United Kingdom
-
Richmond Pharmacology Limited
RECRUITINGLondon, Greater London, SE1 1YR, United Kingdom